Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Moberg Pharma AB (publ)    MOB   SE0003613090

MOBERG PHARMA AB (PUBL)

(MOB)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Moberg Pharma publ : Change in number of shares and votes in Moberg Pharma AB (publ)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/31/2019 | 02:31am EDT

STOCKHOLM, July 31st, 2019, Moberg Pharma AB (OMX: MOB). The number of shares and votes in Moberg Pharma AB (publ) ("Moberg Pharma") has increased by 488,905 ordinary shares in July 2019. Therefore, there are in total 18,853,510 shares and votes in the company as of July 31st 2019, of which 18,192,667 are ordinary shares and 660,843 are shares of series B.

The total number of shares and votes has increased as a result of 488,905 ordinary shares issued after exercise of warrants under Moberg Pharma's share-based incentive program. Due to the exercise of the warrants, the total number of shares and votes has increased by 488,905 from 18,364,605 to 18,853,510 and the share capital has increased by SEK 48,890.50 from SEK 1,836,460.50 to SEK 1,885,351.00.

At the time of this press release the Company holds 184,746 own ordinary shares.

About this information
This information is such that Moberg Pharma AB (publ) is obliged to disclose pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. (CET) on July 31st 2019.

For additional information, please contact:
Anna Ljung, CEO, telephone: +46 707 66 60 30, E-mail: anna.ljung@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's main asset, MOB-015, is a novel topical treatment for onychomycosis, for which phase 3 data in 800+ patients is expected in late 2019 in North America and the first half of 2020 in Europe. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

https://news.cision.com/moberg-pharma/r/change-in-number-of-shares-and-votes-in-moberg-pharma-ab--publ-,c2860433

https://mb.cision.com/Main/1662/2860433/1075362.pdf

(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MOBERG PHARMA AB (PUBL)
07/31MOBERG PHARMA PUBL : Change in number of shares and votes in Moberg Pharma AB (p..
AQ
06/28MOBERG PHARMA PUBL : transfers of own shares completed
PU
06/28MOBERG PHARMA PUBL : transfers of own shares completed
AQ
06/27MOBERG PHARMA PUBL : The Board of Directors of Moberg Pharma AB has resolved to ..
PU
06/27MOBERG PHARMA PUBL : The Board of Directors of Moberg Pharma AB has resolved to ..
AQ
06/25MOBERG PHARMA PUBL : ´s nomination committee appointed
PU
06/25MOBERG PHARMA PUBL : nomination committee appointed
AQ
05/15MOBERG PHARMA PUBL : Bulletin from Moberg Pharma's AGM 2019
AQ
05/14MOBERG PHARMA AB : interim report January - March 2019
AQ
05/07MOBERG PHARMA PUBL : report for the first quarter to be published on May 14 - In..
PU
More news
Financials (SEK)
Sales 2019 117 M
EBIT 2019 6,00 M
Net income 2019 -19,0 M
Finance 2019 98,0 M
Yield 2019 -
P/E ratio 2019 -60,6x
P/E ratio 2020 -58,1x
EV / Sales2019 9,41x
EV / Sales2020 43,0x
Capitalization 1 199 M
Chart MOBERG PHARMA AB (PUBL)
Duration : Period :
Moberg Pharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOBERG PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 87,00  SEK
Last Close Price 64,20  SEK
Spread / Highest target 35,5%
Spread / Average Target 35,5%
Spread / Lowest Target 35,5%
EPS Revisions
Managers
NameTitle
Peter Gunnar Maurits Wolpert Chief Executive Officer
Thomas Lennart Eklund Chairman
Anna Ljung Chief Financial Officer
Shaw Sorooshian Chief Medical Officer & Vice President
Geert Cauwenbergh Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MOBERG PHARMA AB (PUBL)49.30%123
JOHNSON & JOHNSON1.15%344 517
ROCHE HOLDING LTD.12.24%235 575
ROCHE HOLDING13.20%235 575
MERCK AND COMPANY11.32%213 689
NOVARTIS17.81%202 958